Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1399839

	registered interest
	date	05/01/2022
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Vaccine Manufacturing and Innovation Centre: Sales
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether his Department held discussions with scientific bodies prior to the decision to sell the Vaccine Manufacturing and Innovation Centre.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	98275
	answer	answer is ministerial correction date of answer 11/01/2022 answer text <p>The Vaccine Manufacturing Innovation Centre (VMIC) UK is a private company, limited by guarantee, and as such the UK Government does not exercise any ownership rights.</p><p> </p><p>VMIC has been granted £206m of Government funding to date to support the delivery of the facility, including grants since the beginning of the COVID-19 pandemic to increase vaccine manufacturing capacity. Reflecting the public funding VMIC has received, UK Research and Innovation (who have been managing the grant on behalf of the Vaccine Taskforce) will be required to ‘consent’ to any sale of the company or its assets and have confirmed that they will work closely with the Vaccine Taskforce in performing this function.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 98277 question first answered 11/01/2022 17:34:24 answering member 4020 label Biography information for George Freeman previous answer version 42089 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4124 label Biography information for Chi Onwurah

1400058

	registered interest
	date	05/01/2022
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Vaccine Manufacturing and Innovation Centre: Investment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 5 January 2022 to Question 94362, how much has the Government invested in the Vaccine Manufacture and Innovation Centre since its inception (a) directly and (b) through its agencies; and what other forms of control does the Government exercise of that Centre.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	98277
	answer	answer is ministerial correction date of answer 11/01/2022 answer text <p>The Vaccine Manufacturing Innovation Centre (VMIC) UK is a private company, limited by guarantee, and as such the UK Government does not exercise any ownership rights.</p><p> </p><p>VMIC has been granted £206m of Government funding to date to support the delivery of the facility, including grants since the beginning of the COVID-19 pandemic to increase vaccine manufacturing capacity. Reflecting the public funding VMIC has received, UK Research and Innovation (who have been managing the grant on behalf of the Vaccine Taskforce) will be required to ‘consent’ to any sale of the company or its assets and have confirmed that they will work closely with the Vaccine Taskforce in performing this function.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 98275 question first answered 11/01/2022 17:34:24 answering member 4020 label Biography information for George Freeman previous answer version 42090 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4124 label Biography information for Chi Onwurah

1682580

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ivacaftor/tezacaftor/elexacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the potential cost of Kaftrio for the NHS, in the context of the cost of Kaftrio in the EU market.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	9817
	answer	answer is ministerial correction date of answer 19/01/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that develops recommendations on whether medicines represent a clinically and cost-effective use of National Health Service resources at the price proposed by the company. Companies can agree discounts on the price of medicines in the context of the NICE evaluation process.</p><p>NICE is currently developing guidance for the NHS on the clinical and cost effectiveness of Kaftrio and other cystic fibrosis medicines, and recently consulted on its draft recommendations. Kaftrio is currently available as a treatment option for eligible NHS patients under the terms of an interim access agreement, which was originally reached in 2019.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 9818 question first answered 19/01/2024 10:14:15 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4124 label Biography information for Chi Onwurah

1682581

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ivacaftor/tezacaftor/elexacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits of the use of Kaftrio in the NHS.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	9818
	answer	answer is ministerial correction date of answer 19/01/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that develops recommendations on whether medicines represent a clinically and cost-effective use of National Health Service resources at the price proposed by the company. Companies can agree discounts on the price of medicines in the context of the NICE evaluation process.</p><p>NICE is currently developing guidance for the NHS on the clinical and cost effectiveness of Kaftrio and other cystic fibrosis medicines, and recently consulted on its draft recommendations. Kaftrio is currently available as a treatment option for eligible NHS patients under the terms of an interim access agreement, which was originally reached in 2019.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 9817 question first answered 19/01/2024 10:14:15 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4124 label Biography information for Chi Onwurah

1387871

	registered interest
	date	14/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to deliver a MedTech strategy; what the objectives of that strategy will be; what metrics will be used to assess progress on those objectives; and what resource is being allocated to the delivery of that strategy.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	92930
	answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>The Medical Technology Directorate is currently working on a strategy, due for publication next year. The strategy will support the United Kingdom MedTech sector and ensure the health and social care system can reliably access safe, effective and innovative medical technologies that support the continued delivery of high-quality care and excellent patient outcomes and represents value for money. When published, the strategy will set out the longer term aims and metrics and the vision for implementation, including the resources required for successful delivery. As part of the strategy’s development, the Directorate are engaging with key stakeholders, including industry and wider Government teams. The strategy will align with and be complementary to the Life Sciences Vision.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 92931 92932 question first answered 20/12/2021 10:23:35 answering member 4362 label Biography information for Edward Argar
	tabling member	4124 label Biography information for Chi Onwurah

1387872

	registered interest
	date	14/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to engage with (a) the medical technology industry and (b) other relevant stakeholders on the development of a MedTech strategy.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	92931
	answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>The Medical Technology Directorate is currently working on a strategy, due for publication next year. The strategy will support the United Kingdom MedTech sector and ensure the health and social care system can reliably access safe, effective and innovative medical technologies that support the continued delivery of high-quality care and excellent patient outcomes and represents value for money. When published, the strategy will set out the longer term aims and metrics and the vision for implementation, including the resources required for successful delivery. As part of the strategy’s development, the Directorate are engaging with key stakeholders, including industry and wider Government teams. The strategy will align with and be complementary to the Life Sciences Vision.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 92930 92932 question first answered 20/12/2021 10:23:35 answering member 4362 label Biography information for Edward Argar
	tabling member	4124 label Biography information for Chi Onwurah

1387873

	registered interest
	date	14/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Technologies Directorate: Life Sciences
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the role of the Medical Technology Directorate is in supporting the implementation of the Life Sciences Vision. .
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	92932
	answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>The Medical Technology Directorate is currently working on a strategy, due for publication next year. The strategy will support the United Kingdom MedTech sector and ensure the health and social care system can reliably access safe, effective and innovative medical technologies that support the continued delivery of high-quality care and excellent patient outcomes and represents value for money. When published, the strategy will set out the longer term aims and metrics and the vision for implementation, including the resources required for successful delivery. As part of the strategy’s development, the Directorate are engaging with key stakeholders, including industry and wider Government teams. The strategy will align with and be complementary to the Life Sciences Vision.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 92930 92931 question first answered 20/12/2021 10:23:35 answering member 4362 label Biography information for Edward Argar
	tabling member	4124 label Biography information for Chi Onwurah

1387866

	registered interest
	date	14/12/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Innovate UK: Expenditure
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, if he will provide a breakdown of Innovate UK expenditure during the financial year ended 5 April 2021 of (a) employees, (b) individual contractors and consultations, excluding KTN, (c) other Innovate UK operational spending and overheads, (d) Industrial Strategy Challenge Fund grants, (e) other R&D grants, (f) SBRI contracts, excluding contract funding coming from other parts of the public sector, (g) loans to businesses, (h) core funding of catapults, (i) KTN operations, (j) other Innovate UK programmes and (k) other expenditures; and if he will make an estimate of how those annual expenditures are planned to change over the Spending Review.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	92927
	answer	answer is ministerial correction date of answer 22/12/2021 answer text <p>A breakdown of expenditure for the whole of UKRI is set out in the UKRI annual report and accounts for 2020-21 (Note 2 Page 158)<a href="https://ukc-word-edit.officeapps.live.com/we/wordeditorframe.aspx?ui=en%2DGB&amp;rs=en%2DGB&amp;wopisrc=https%3A%2F%2Fbeisgov.sharepoint.com%2Fsites%2FSRIDPIR%2F_vti_bin%2Fwopi.ashx%2Ffiles%2F903011565e784d59b5abe5986c53788a&amp;wdenableroaming=1&amp;mscc=1&amp;hid=5B670DA0-00DE-3000-69EA-38754761EC2F&amp;wdorigin=ItemsView&amp;wdhostclicktime=1639675651478&amp;jsapi=1&amp;jsapiver=v1&amp;newsession=1&amp;corrid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;usid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;sftc=1&amp;mtf=1&amp;sfp=1&amp;instantedit=1&amp;wopicomplete=1&amp;wdredirectionreason=Unified_SingleFlush&amp;preseededsessionkey=6442766a-a6fd-0807-bde5-12f66f20a817&amp;preseededwacsessionid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;rct=Medium&amp;ctp=LeastProtected#_ftn1" target="_blank"><sup>[1]</sup></a>.</p><p><em><a href="https://ukc-word-edit.officeapps.live.com/we/wordeditorframe.aspx?ui=en%2DGB&amp;rs=en%2DGB&amp;wopisrc=https%3A%2F%2Fbeisgov.sharepoint.com%2Fsites%2FSRIDPIR%2F_vti_bin%2Fwopi.ashx%2Ffiles%2F903011565e784d59b5abe5986c53788a&amp;wdenableroaming=1&amp;mscc=1&amp;hid=5B670DA0-00DE-3000-69EA-38754761EC2F&amp;wdorigin=ItemsView&amp;wdhostclicktime=1639675651478&amp;jsapi=1&amp;jsapiver=v1&amp;newsession=1&amp;corrid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;usid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;sftc=1&amp;mtf=1&amp;sfp=1&amp;instantedit=1&amp;wopicomplete=1&amp;wdredirectionreason=Unified_SingleFlush&amp;preseededsessionkey=6442766a-a6fd-0807-bde5-12f66f20a817&amp;preseededwacsessionid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;rct=Medium&amp;ctp=LeastProtected#_ftnref1" target="_blank"><sup>[1]</sup></a> <a href="https://www.ukri.org/wp-content/uploads/2021/07/UKRI-200721-AnnualReport2020-2021.pdf" target="_blank">UKRI-200721-AnnualReport2020-2021.pdf</a></em></p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 92928 question first answered 22/12/2021 14:17:09 answering member 4020 label Biography information for George Freeman
	tabling member	4124 label Biography information for Chi Onwurah

1387867

	registered interest
	date	14/12/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Innovation: Expenditure
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, if he will provide a breakdown of innovation policy expenditure during the financial year ended 5 April 2021 of (a) employees, (b) individual contractors and consultations, excluding KTN, (c) other Innovate UK operational spending and overheads, (d) Industrial Strategy Challenge Fund grants, (e) other R&D grants, (f) SBRI contracts, excluding contract funding coming from other parts of the public sector, (g) loans to businesses, (h) core funding of catapults, (i) KTN operations, (j) other Innovate UK programmes and (k) other expenditures; and if he will make an estimate of how those annual expenditures are expected to change over the next three years.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	92928
	answer	answer is ministerial correction date of answer 22/12/2021 answer text <p>A breakdown of expenditure for the whole of UKRI is set out in the UKRI annual report and accounts for 2020-21 (Note 2 Page 158)<a href="https://ukc-word-edit.officeapps.live.com/we/wordeditorframe.aspx?ui=en%2DGB&amp;rs=en%2DGB&amp;wopisrc=https%3A%2F%2Fbeisgov.sharepoint.com%2Fsites%2FSRIDPIR%2F_vti_bin%2Fwopi.ashx%2Ffiles%2F903011565e784d59b5abe5986c53788a&amp;wdenableroaming=1&amp;mscc=1&amp;hid=5B670DA0-00DE-3000-69EA-38754761EC2F&amp;wdorigin=ItemsView&amp;wdhostclicktime=1639675651478&amp;jsapi=1&amp;jsapiver=v1&amp;newsession=1&amp;corrid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;usid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;sftc=1&amp;mtf=1&amp;sfp=1&amp;instantedit=1&amp;wopicomplete=1&amp;wdredirectionreason=Unified_SingleFlush&amp;preseededsessionkey=6442766a-a6fd-0807-bde5-12f66f20a817&amp;preseededwacsessionid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;rct=Medium&amp;ctp=LeastProtected#_ftn1" target="_blank"><sup>[1]</sup></a>.</p><p><em><a href="https://ukc-word-edit.officeapps.live.com/we/wordeditorframe.aspx?ui=en%2DGB&amp;rs=en%2DGB&amp;wopisrc=https%3A%2F%2Fbeisgov.sharepoint.com%2Fsites%2FSRIDPIR%2F_vti_bin%2Fwopi.ashx%2Ffiles%2F903011565e784d59b5abe5986c53788a&amp;wdenableroaming=1&amp;mscc=1&amp;hid=5B670DA0-00DE-3000-69EA-38754761EC2F&amp;wdorigin=ItemsView&amp;wdhostclicktime=1639675651478&amp;jsapi=1&amp;jsapiver=v1&amp;newsession=1&amp;corrid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;usid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;sftc=1&amp;mtf=1&amp;sfp=1&amp;instantedit=1&amp;wopicomplete=1&amp;wdredirectionreason=Unified_SingleFlush&amp;preseededsessionkey=6442766a-a6fd-0807-bde5-12f66f20a817&amp;preseededwacsessionid=cf205dda-3ddc-56f0-a087-c3c83c023342&amp;rct=Medium&amp;ctp=LeastProtected#_ftnref1" target="_blank"><sup>[1]</sup></a> <a href="https://www.ukri.org/wp-content/uploads/2021/07/UKRI-200721-AnnualReport2020-2021.pdf" target="_blank">UKRI-200721-AnnualReport2020-2021.pdf</a></em></p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 92927 question first answered 22/12/2021 14:17:09 answering member 4020 label Biography information for George Freeman
	tabling member	4124 label Biography information for Chi Onwurah

1235982

	registered interest
	date	22/09/2020
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	British Patient Capital
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what the average time from application to funding decision is for British Patient Capital.
	tabling member constituency	Newcastle upon Tyne Central
	tabling member printed	Chi Onwurah
	uin	92649
	answer	answer is ministerial correction date of answer 30/09/2020 answer text <p>As part of the Patient Capital Review, the Government consulted on potential barriers to accessing finance and the means to overcome them. Following the review’s conclusion in November 2017, my Rt. Hon. Friend Mr Chancellor of the Exchequer announced an action plan to unlock over £20 billion to finance growth in innovative firms over 10 years. The plan included additional resources for the British Business Bank, and the creation of its commercial subsidiary, British Patient Capital.</p><p> </p><p>Established in 2018, British Patient Capital builds on over a decade of investing £1bn in venture and venture growth capital funds. Several of these funds are now major names in UK venture, and many of the British Patient Capital team bring with them the experience, knowledge and relationships gained working in predecessor programmes. These relationships and British Patient Capital’s reputation allow it to see and take advantage of opportunities others may not. British Patient Capital predominantly invests as a Limited Partner investor.</p><p> </p><p>At the end of the last financial year, British Patient Capital’s portfolio consisted of 31 fund investments, with total commitments approaching £600m, making British Patient Capital the largest domestic investor in this asset class in the UK. Page 21 of British Patient Capital’s Annual Report and Accounts 2019 provides a sectoral breakdown and is available here: <a href="https://annualreport2019.britishpatientcapital.co.uk/assets/uploads/BPC_Annual_Report_2019.pdf" target="_blank">https://annualreport2019.britishpatientcapital.co.uk/assets/uploads/BPC_Annual_Report_2019.pdf</a>.</p> answering member constituency Sutton and Cheam answering member printed Paul Scully grouped question UIN 92650 92653 92654 question first answered 30/09/2020 15:16:34 answering member 4414 label Biography information for Paul Scully
	tabling member	4124 label Biography information for Chi Onwurah